Adlai Nortye Ltd. (NASDAQ:ANL - Get Free Report) was the target of a large growth in short interest in March. As of March 31st, there was short interest totalling 6,400 shares, a growth of 48.8% from the March 15th total of 4,300 shares. Based on an average trading volume of 6,900 shares, the days-to-cover ratio is currently 0.9 days. Currently, 0.0% of the shares of the stock are short sold.
Adlai Nortye Stock Performance
Shares of ANL traded up $0.05 on Wednesday, reaching $2.05. The stock had a trading volume of 6,676 shares, compared to its average volume of 12,870. The firm has a 50-day moving average of $2.14 and a 200 day moving average of $2.20. Adlai Nortye has a twelve month low of $1.69 and a twelve month high of $14.90.
About Adlai Nortye
(
Get Free Report)
Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.
See Also
Before you consider Adlai Nortye, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adlai Nortye wasn't on the list.
While Adlai Nortye currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
